Compact Line-scanning Adaptive Optics Retinal Imager

描述（由申请人提供）：物理科学公司（PSI）在与杜克眼科中心的眼科医生协商后，提出了一种紧凑型自适应光学线扫描激光检眼镜（AO-LSLO）的开发。该仪器将大大减少自适应光学视网膜相机的尺寸、成本和复杂性，并导致眼科医生、验光师和视觉研究人员更广泛地使用高分辨率成像技术。在拟议的第一阶段计划中，我们将设计和建模光学布局，构建仪器的台式版本，并完成一系列实验来表征和优化性能并确定概念可行性。在潜在的第二阶段项目中，我们将把装置包装到一个小的外壳中，设计成坐在裂隙灯舞台上。我们还将在杜克眼科中心对患有视网膜疾病的人类受试者进行临床试验，这是二期项目的后半部分。该仪器将适用于视网膜疾病的早期检测和进展的临床研究，直接测量各种视网膜缺陷的结构和功能特征，显微视野测量和心理物理视觉研究，以及确定新的遗传和分子疗法的疗效。通过使高分辨率的眼部访问更广泛，该仪器将开始将自适应光学技术推向更多的临床医生和科学家。反过来，这些研究人员将使用这个工具来增加我们对视力的理解，以及疾病对视力的破坏，并开发新的药物和治疗方法。

DESCRIPTION (provided by applicant): Physical Sciences Inc. (PSI), in consultation with an ophthalmologist from Duke Eye Center, proposes the development of a compact adaptive optics line-scanning laser ophthalmoscope (AO-LSLO). The instrument will greatly reduce the size, cost, and complexity of adaptive optics retinal cameras and lead to more wide-spread use of high-resolution imaging technology by ophthalmologist, optometrist, and vision researchers. In the proposed Phase I program, we will design and model the optical layout, construct a bench-top version of the instrument, and complete a series of experiments to characterize and optimize performance and determine concept feasibility. In a potential Phase II program, we will package the setup into a small housing designed to sit on a slit lamp stage. We will also perform clinical testing on human subjects with retinal diseases at Duke Eye Center in the second half of a Phase II program. The instrument will be amenable to clinical studies for the early detection and progression of retinal disease, direct measurement of the structural and functional characteristics of a wide range of retinal defects, microperimetry and psychophysical vision studies, and for determination of the efficacy of novel genetic and molecular therapies. By making high-resolution ocular access more widespread, the proposed instrument will begin to move adaptive optics technology into a greater number of clinicians and scientists. These researchers will, in turn, use this tool to increase our understanding of vision and its disruption by disease and for the development of new drugs and therapies.